Amivantamab and lazertinib combination therapy shows high efficacy in EGFR-mutated NSCLC, with an 82% objective response rate in the PALOMA-2 trial. Subcutaneous administration of amivantamab reduces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results